Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C

Journal of Viral Hepatitis

Volumn 11, Issue 3, 2004, Pages 206-216

  Marinho, R T ^a,b   Pinto, R ^a   Santos, M L ^a   Lobos, I V ^a   Moura, M C ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b Medical School of Lisbon   (Portugal)

Author keywords

CD4 positive; Cytokines; Hepatitis C; Interferon alpha; Lymphocyte activation; Ribavirin; T lymphocytes

Indexed keywords

CD38 ANTIGEN; CD69 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; STATISTICAL ANALYSIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TH1 CELLS; TH2 CELLS; VIREMIA;

EID: 2442680434     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00496.x     Document Type: Article

References (67)

1. Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 1997: 4(Suppl. 2): 31S-41S.
2. Ferrari C, Urbani S, Penna A et al. Immunopathogenesis of hepatitis C virus infection. J Hepatol 1999; 31(Suppl. 1): 31S-38S.
3. Schirren C, Jung MC, Gerlach J et al. Liver-derived hepatitis C virus (HCV)-speciflc CD4+ T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 2000; 32; 597-603.
4. Ferrari C, Valli A, Galati L et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286-295.
5. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre and posttreatment with Interferon alfa. Hepatology 1996; 24: 6-9.
6. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Ohmiya M, Tani Y. Serum levels of soluble interleukin-2 receptors and effects of interferon-α for patients with chronic hepatitis C virus. Dig Dis Sci 1995; 40: 1837-1841.
7. Quiroga J, Martin J, Pardo M, Carreño V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig Dis Sci 1994; 39: 2485-2496.
8. Leroux-Roels G, Esquivel C, DeLeys R et al. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alpha. Hepatology 1996: 23: 8-16.
9. Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007.
10. Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-941.
11. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. J Immunol 1986; 136: 2348-2357.
12. McCaughan GW, Napoli J, McGuiness P, Bishop GA. T1 vs. T2 cytokine responses in chronic HCV: implications for mechanisms of liver injury. Viral Hepat Rev 1997; 3: 129-142.
13. Oriss TB, McCarthy SA, Morel BF, Campana MA, Morel PA. Crossregulation between T helper cell (Th)1 and Th2. J Immunol 1997; 158: 3666-3672.
14. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
15. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treat-ment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
16. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
17. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
18. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001: 358: 958-965.
19. Fried MW, Shiffman ML, Reddy R et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
20. Tam RC, Pai B, Bard J et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30: 376-382.
21. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 2381-2391.
22. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996; 23: 909-16.
23. Foster GH. Interferons in host defense. Semin Liver Dis 1997; 17: 287-295.
24. Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993; 178: 537-547.
25. Cramp ME, Carucci P, Rossol S et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999; 44: 424-429.
26. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Gerlach T, Pape GR. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 1996; 74: 583-588.
27. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128: 195-203.
28. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99: 1566-1568.
29. Ulsenheimer A, Gerlach JT, Gruener NH et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C Hepatology 2003; 37: 1189-1198.
30. Hempel G, Galle PR, Löhr HF. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha- treated patients with chronic hepatitis C. J Med Virol 2001; 64: 340-349.
31. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. Novel CD4+ and CDS+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37: 577-589.
32. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-714.
33. Lechmann M, Ihlenfeldt H, Braunschweiger I et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C virus infection and healthy anti-hepatitis C virus-positive blood donors without viremia, Hepatology 1996; 24: 790-795.
34. Hoffmann RM, Diepolder HM, Zachoval R et al. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995; 21: 632-638.
35. Sreenarasimhaiah J, Jaramillo A, Crippin J, Lisker-Melman M, Chapman WC, Mohanakumar T. Concomitant augmentation of type 1 CD4(+) and CD8(+) T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol 2003; 64: 497-504.
36. Zhang Z, Milich D, Peterson D et al. Interferon-α treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis 1997; 175: 1294-1301.
37. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-355.
38. Löhr HF, Gerken G, Roth M, Weyer S, Schlaak JF, Meyer zum Büschenfelde KH. The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. J Hepatol 1998; 29: 524-532.
39. Missale G, Cariani E, Lamonaca V et al. Effects of Interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26: 792-797.
40. Valdez H, Anthony D, Farukhi F et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000; 14: 2239-2246.
41. Neuman MG, Benhamou JP, Martinot M et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999; 32: 537-545.
42. Naveau S, Balian A, Degos F, Daurat V, Chevret S. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. J Hepatol 1999; 31: 612-617.
43. Sugimura T, Motomura S, Sakai H, Nawata H. Increased serum soluble IL-2 receptor levels following interferon therapy in patients with chronic hepatitis C. Hepatogastroenterology 1999; 46: 1827-30.
44. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263-266.
45. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-458.
46. Koziel MJ, Dudley D, Afdhal N et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995; 96: 2311-2321.
47. Bertoletti A, D'Elios MM, Boni C et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193-199.
48. Kobayashi K, Ishii M, Igarashi T, Satoh T, Miyazaki Y, Yajima Y et al. Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C. J Gastroenterol 1998; 33: 500-507.
49. Lazdina U, Hultgren C, Frelin L et al. Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 2001; 82: 1299-1308.
50. Akdis C, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001; 103: 131-136.
51. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438-1447.
52. Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192-198.
53. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609.
54. Reiser M, Marousis CG, Nelson DR et al. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol 1997; 26: 471-478.
55. Sarobe P, Jauregui JI, Lasarte JJ et al. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C; relationship with response to interferon treatment. J Hepatol 1996; 25: 1-9.
56. Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1997; 108; 138-143.
57. Eckels DD, Tabatabail N, Bian TH et al. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. Hum Immunol 1999; 60: 187-199.
58. Cargnel A, Gubertini G, Magnani C, Bosis S, Colombo F, Clerici M. Immune response in chronic hepatitis C-infected patients undergoing interferon treatment. Hepatology 1999; 30: 584-585.
59. Shapiro S, Gershtein V, Elias N, Zuckerman E, Salman N, Lahat N. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha treatment. Clin Exp Immunol 1998; 114: 55-60.
60. Martín J, Quiroga J, Navas S, Pardo M, Carreño V. Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine 1999: 11: 267-273.
61. Kuzushita N, Hayashi N, Katayama K et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997; 32: 169-74.
62. Bergamini A, Bolacchi F, Cerasari G et al. Lack of evidence for the Th2 predominance in patients with chronic hepatitis C. Clin Exp Immunol 2001; 123: 451-458.
63. Wejstal R, Norkrans G, Weiland O et al. Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/ non-A, non-B. Effects of interferon-alpha treatment. Clin Exp Immunol 1992; 87: 340-345.
64. Russo-Mancuso G, Di Gregorio F, Passero E et al. Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to alpha-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study. Br J Haematol 1995; 89: 291-298.
65. Chan TM, Ho SK, Lai CL, Cheng IK, Lai KN. Lymphocyte subsets in renal allograft recipients with chronic hepatitis C virus infection. Nephrol Dial Transplant 1999; 14: 717-722.
66. Lechner F, Gruener NH, Urbani S et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000; 30: 2479-2487.
67. Appasamy R, Bryant J, Hassanein T, Van Thiel DH, Whiteside TL. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C. Clin Immunol Immunopathol 1994; 73: 350-357.